Matinas BioPharma to Pivot Into Clean Energy via GH Power Merger
Matinas BioPharma is merging with GH Power to form a public clean energy firm while selling its drug tech to Azurity Pharmaceuticals.
Matinas BioPharma is making a dramatic corporate U-turn, announcing plans to combine with GH Power in a deal that would transform the pharmaceutical company into a publicly traded clean energy player. The new entity will zero in on modular carbon-free energy, green hydrogen, critical materials, and industrial decarbonization — four of the hottest buzzwords in the energy transition space right now.
If you're not familiar with green hydrogen, here's the quick version: it's hydrogen fuel produced using renewable electricity rather than fossil fuels, making it a potential game-changer for industries that are tough to electrify, like steel manufacturing and heavy shipping. By folding GH Power's expertise into a publicly listed vehicle, the combined company aims to give everyday investors a cleaner way to bet on the hydrogen economy.
Read more TeraWulf CEO Says Power Quality Sets Winners in AI Race →
At the same time, Matinas isn't just walking away from its pharmaceutical roots empty-handed. The company has signed a definitive agreement to sell its lipid nanocrystal (LNC) drug delivery platform technology — along with its lead drug candidate, MAT2203 — to Azurity Pharmaceuticals. That sale effectively packages up Matinas's core biotech assets and hands them off to a buyer better positioned to develop them, while freeing Matinas to fully commit to its energy ambitions.
The dual-deal structure is a savvy way to fund a pivot: sell what you have, buy into what you want to become. For shareholders, the big question will be whether the GH Power business can deliver real revenue in a sector that has seen plenty of hype but uneven commercial progress. The modular and decarbonization angles suggest the company wants to court industrial customers, not just make headlines.
Continue reading at GlobalNewswire.
